Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00883155 | To Demonstrate the Relative Bioavailability of Bupropion HCI 100 mg Tablets Under Fasting Conditions | PHASE1 | COMPLETED | 36 | — | — | Oct 1, 1998 | Oct 1, 1998 | Mar 29, 2017 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Bupropion HCl 100 mg Tablets (Invamed Inc.) |
| 2 | ACTIVE_COMPARATOR | Wellbutrin 100 mg Tablets (Glaxo Wellcome) |
| Name | Type | Description |
|---|---|---|
| Bupropion HCl 100 mg Tablets (Invamed Inc.) | DRUG | - |
| Wellbutrin 100 mg Tablets (Glaxo Wellcome) | DRUG | - |
Inclusion Criteria: * No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. Exclusion Criteria: * Positive test results for HIV or hepatitis B or C. * Treatment for drug or alcohol dependence.